18β-glycyrrhetinic acid Mitigates bisphenol A-induced liver and renal damage: Inhibition of TNF-α/NF-κB/p38-MAPK, JAK1/STAT1 pathways, oxidative stress and apoptosis
Food and Chemical Toxicology · 2025-02 · 196 · 115218
DOI: 10.1016/j.fct.2024.115218 ↗Kurz gefasst
Fachartikel in der Zeitschrift Food and Chemical Toxicology, 2025-02. Verfasst von Ekrem Darendelioglu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Genetics, Faculty of Science and Literature, Bingol University, Bingol, Turkey. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glycyrrhetinic Acid, Phenols, Oxidative Stress. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Bingol University.
Abstract (Originalsprache)
Bisphenol A (BPA) has been commonly used in various consumer products, including water bottles, food containers, and canned food linings. However, there are concerns about its potential toxicity to human health, particularly its impact on the liver and kidneys. The objective of this research was to investigate the potential ameliorative effects of 18β-glycyrrhetinic acid (GA) against BPA-induced hepatotoxicity and nephrotoxicity in rats. The animals were supplemented with BPA (250 mg/kg b.w.) alone or with GA (50 and 100 mg/kg b.w.) for 14 days. GA treatment alleviated the BPA-induced hepato-renal tissue injuries through reducing the serum ALT, AST and ALP levels, and urea and creatinine levels. GA co-treatment also increased activities of SOD, CAT and GPx enzymes and levels of GSH, and suppressed MDA levels in BPA induced tissues. BPA also induced inflammation by increasing the levels of TNF-α, NF-κB, JAK1, STAT1, P38 MAPK and JNK in liver and kidney tissues and GA treatment ameliorated these effects. BPA triggered apoptosis by increasing caspase-3, Bax, and cytochrome c at protein levels and also by decreasing the antiapoptotic Bcl-2 level. However, treatment with GA (50 and 100 mg/kg) decreased apoptosis. Overall, our results have revealed the potential ameliorative mechanisms of GA, as a possible agent for BPA-induced hepatotoxicity and nephrotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology and Genetics, Faculty of Science and Literature, Bingol University, Bingol, Turkey.
- Department of Medical Biochemistry, Faculty of Medicine, Bilecik Şeyh Edebali University, Bilecik, Turkey.
- Department of Biochemistry, Faculty of Veterinary Medicine, Atatürk University, Erzurum, Turkey.
- Department of Medical Biology, Faculty of Medicine, Pamukkale University, Denizli, Turkey. Electronic address: ibayav22@posta.pau.edu.tr.
- Department of Medical Biochemistry, Faculty of Medicine, Aksaray University, Aksaray, Turkey.
- Department of Chemistry, Faculty of Science and Literature, Bingol University, Bingol, Turkey.
Förderung
- Bingol University
Zitieren
APA
Darendelioglu, E., Caglayan, C., Küçükler, S., Bayav, İ., Kandemir, F. M., Ayna, A., & Sağ, S. (2025). 18β-glycyrrhetinic acid Mitigates bisphenol A-induced liver and renal damage: Inhibition of TNF-α/NF-κB/p38-MAPK, JAK1/STAT1 pathways, oxidative stress and apoptosis. Food and Chemical Toxicology, 196, 115218. https://doi.org/10.1016/j.fct.2024.115218
Vancouver
Darendelioglu E, Caglayan C, Küçükler S, Bayav İ, Kandemir FM, Ayna A, et al. 18β-glycyrrhetinic acid Mitigates bisphenol A-induced liver and renal damage: Inhibition of TNF-α/NF-κB/p38-MAPK, JAK1/STAT1 pathways, oxidative stress and apoptosis. Food and Chemical Toxicology. 2025;196:115218. doi:10.1016/j.fct.2024.115218
BibTeX
@article{Darendelioglu2025,
author = {Darendelioglu, Ekrem and Caglayan, Cuneyt and Küçükler, Sefa and Bayav, İbrahim and Kandemir, Fatih Mehmet and Ayna, Adnan and Sağ, Sevda},
title = {18β-glycyrrhetinic acid Mitigates bisphenol A-induced liver and renal damage: Inhibition of TNF-α/NF-κB/p38-MAPK, JAK1/STAT1 pathways, oxidative stress and apoptosis},
journal = {Food and Chemical Toxicology},
year = {2025},
volume = {196},
pages = {115218},
doi = {10.1016/j.fct.2024.115218}
}
EUVIMED